STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia
Open Access
- 4 April 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 19 (5) , 536-544
Abstract
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is an active mediator of cytokine signaling in the pathogenesis of solid and hematologic malignancies. The seven-member STAT family is composed of latent cytoplasmic transcription factors that are activated by phosphorylation intertwined in a network with activation that ultimately leads to cell proliferation. An activated kinase enzyme phosphorylates one STAT factor or more, which shuttle to the nucleus to regulate gene expression, promoting cell survival. Somatic STAT3 mutations have been recently reported in large granular lymphocytic leukemia, aplastic anemia, and myelodysplastic syndrome. Furthermore, the relationship between BCL6 and STAT3 in diffuse large B-cell lymphomas, particularly on the activated B-cell subtype, needs to be further explored. The search for therapeutic STAT3 inhibitors that abrogate the JAK/STAT pathway is currently under way. Targeting the STAT pathway, which seems to be critical in tumorigenesis, is promising for multiple malignancies including lymphoma and leukemia. In this paper, we review mechanisms of action, failures, and successes of STAT3 inhibitors.Keywords
This publication has 107 references indexed in Scilit:
- Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activationBlood Cancer Journal, 2013
- A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinasesBlood Cancer Journal, 2013
- The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphomaBlood Cancer Journal, 2011
- FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphomaBlood, 2011
- Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myelomaBMC Cancer, 2011
- Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive CellsCancer Research, 2009
- Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomasBlood, 2008
- Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasJournal of Clinical Investigation, 2007
- Oncogenic Ras-induced secretion of IL6 is required for tumorigenesisGenes & Development, 2007
- Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activityProceedings of the National Academy of Sciences, 2007